Abiopharma

🔍 SHARP KENNETH P (Executive)

Company: L3HARRIS TECHNOLOGIES, INC. /DE/ (LHX)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 10,021 shares of Non-Qualified Stock Option (Right to Buy) at $313.37 per share (Derivative)
  Date: 2026-05-01 | Code: A | Expires: 2036-05-01 | equity_swap_involved: 0 | shares_owned_after: 10,021.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Acquired 2,593 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,593.00 | transaction_form_type: 4 | Footnotes: F2, F2
• Acquired 11,169 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 11,169.00 | transaction_form_type: 4 | Footnotes: F3, F3

Footnotes:

• F1: Grant of options to purchase shares of the Issuer's common stock subject to 3-year ratable vesting on 5/1/2027, 5/1/2028 and 5/1/2029, subject to continued employment (with certain exceptions) and the terms and conditions of the stock option award agreement.
• F2: Award of restricted stock units subject to 3-year cliff vesting on 5/1/2029, subject to continued employment (with certain exceptions) and the terms and conditions of the restricted unit award agreement. Each restricted stock unit represents a contingent right to one share of the Issuer's common stock, with vested units settled in shares of the Issuer's common stock.
• F3: Award of restricted stock units subject to future 4-year ratable vesting on 5/1/2027, 5/1/2028, 5/1/2029, and 5/1/2030, subject to continued employment (with certain exceptions) and the terms and conditions of the restricted unit award agreement. Each restricted stock unit represents a contingent right to one share of the Issuer's common stock, with vested units settled in shares of the Issuer's common stock.